ClinicalTrials.gg
RecruitingNCT06845410Updated Nov 19, 2025

Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study

An observational study in Coronary Artery Disease, Coronary Artery Disease Progression and Coronary Artery Stenosis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Peking Union Medical College Hospital.

Started
2025
with 1 other
Observational
5 of 10
4 open now
Registered
9th of 10
by date

Among the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 9th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

This is a cohort study to investigate the clinical features, current treatment and clinical outcomes in patients with inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD).

Read the detailed description

A special type of coronary artery disease (CAD) has been identified in our clinical practice. The patients have significantly different clinical features from those of typical atherosclerotic coronary artery disease (AS-CAD), including: 1) predominantly female; 2) early onset CAD; 3) lack of traditional atherosclerotic risk factors; 4) often with evidence of chronic inflammation; 5) responding poorly to intensified secondary prevention and optimized coronary revascularization (percutaneous coronary intervention [PCI] or coronary bypass graft [CABG]); 6) delayed disease progression on immunosuppressive therapy. This special type of CAD is named with inflammation-associated coronary artery disease (I-CAD). Currently, the pathogenesis as well as the optimal approach regarding the diagnosis and treatment of I-CAD remain unknown.

Based on the rate of disease progression and the urgency for clinical management, I-CAD is classified into two categories: 1) inflammation-associated rapidly-progressive coronary artery disease (IR-CAD), which is defined as I-CAD with progression of coronary de novo and/or restenotic lesions within 6 months or within 12 months (only for patients receiving immunosuppressive therapy within 24 months); 2) inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD), which is defined as I-CAD not fulfilling the criteria for IR-CAD.

It has been recognized in our clinical practice that INR-CAD is a highly heterogeneous group of diseases. Therefore, the present observational cohort study was designed to investigate the clinical features, current treatment and clinical outcomes in patients with INR-CAD.

All patients who have been admitted to the Department of Cardiology, Peking Union Medical College Hospital (PUMCH) since January 1, 2022 will be screened for study participation. Clinical diagnostic criteria and a clinical follow-up protocol have been specifically designed for INR-CAD in our center. Patients are clinically diagnosed as INR-CAD if they 1) have angiographic evidence of coronary lesions (de novo or restenotic); 2) have evidence of chronic inflammation (positive inflammatory markers or positive autoantibodies or established diagnosis of chronic inflammatory diseases or use of immunosuppressive therapy) within 24 months; 3) not meet the clinical diagnostic criteria for IR-CAD. Once the clinical diagnosis is established, INR-CAD patients will receive a 24-month clinical follow-up according to the clinical follow-up protocol for INR-CAD in PUMCH. Patients who have been clinically diagnosed as INR-CAD and received, or are receiving, or will receive the 24-month clinical follow-up will be enrolled in the present cohort study.

The primary efficacy endpoint is major adverse cardiovascular events (MACE). The secondary efficacy endpoints include the individual components of MACE, exercise capacity, angiographic metrics of coronary lesions, and inflammatory markers. The safety endpoints are major bleeding events and severe infection events.

For the endpoints which are categorical variables, e.g., MACE, the event rate for the first occurrence of each endpoint during the 24-month clinical follow-up will be calculated. Chi-square test or Fisher's exact test will be used to compare the event rate for each endpoint between patients with different diagnosis and/or those receiving different treatment, including patients 1) with vs. without established diagnosis of chronic inflammatory diseases; 2) receiving vs. not receiving immunosuppressive therapy; 3) receiving vs. not receiving coronary revascularization.

For the endpoints which are continuous variables, e.g., inflammatory markers, 1) paired t-test or paired rank sum test will be used to compare the level of each endpoint at the end of the 24-month clinical follow-up with that at baseline (the diagnosis of INR-CAD); 2) analysis of co-variance (ANCOVA) will be used to compare the level of each endpoint at the end of the 24-month clinical follow-up between patients with different diagnosis and/or those receiving different treatment, including patients ① with vs. without established diagnosis of chronic inflammatory diseases; ② receiving vs. not receiving immunosuppressive therapy; ③ receiving vs. not receiving coronary revascularization.

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Artery Disease Progression
  • Coronary Artery Stenosis
  • Coronary Artery Restenosis
  • Inflammation
  • Inflammatory Disease
  • Inflammation Vascular

Keywords

  • Coronary Artery Disease
  • Progression, Disease
  • Inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who have been admitted to the Department of Cardiology, Peking Union Medical College Hospital (PUMCH) since January 1, 2022 will be screened for study participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older, male or female.
  2. Negative results of urine or blood pregnancy test for females with (not or surgically sterile).
  3. Meeting the clinical diagnostic criteria for -CAD, including: (1) Angiographic evidence of coronary lesions (≥ 50% diameter stenosis, de novo or restenotic); (2) Evidence of chronic inflammation within 24 months: (A) Positive inflammatory markers (erythrocyte sedimentation rate [ESR], high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α], et al; at least twice, ≥ 12 weeks apart), or (B) Positive autoantibodies (at least twice, ≥ 12 weeks apart), or (C) Established diagnosis of chronic inflammatory diseases ( disease, systemic vasculitis, psoriasis, tuberculosis, et al), or (D) Receiving therapy (, immunosuppressive agents, et al).
  4. NOT meeting the clinical diagnostic criteria for IR-CAD, including: (1) Hospitalization due to myocardial ischemia, including: (A) Typical symptoms of angina (Canadian Cardiovascular Society [CCS] III-IV), and (B) Non-invasive evidence of myocardial ischemia; (2) Angiographic evidence of new or worsened coronary lesions (de novo or restenotic) considered relevant to myocardial ischemia, which occurred: (A) Within 6 months of last coronary angiography in any patients, or (B) Within 12 months of last coronary angiography in patients receiving immunosuppressive therapy within 24 months.
  5. Received, or are receiving, or will receive the 24-month clinical follow-up defined by the clinical follow-up protocol for INR-CAD.

Exclusion criteria

Exclusion Criteria:

  1. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
  2. Active (diagnosed within 12 months or with ongoing requirement for treatment).
  3. Vital organ failure.
  4. \< 1 year.
  5. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.
  6. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).
  7. Previous enrollment in this study.
  8. Participation in another study within 30 days.
  9. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).
  10. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • INR-CAD Group

    Patients who have been clinically diagnosed as INR-CAD and received, or are receiving, or will receive the 24-month clinical follow-up according to the clinical diagnostic criteria and follow-up protocol for INR-CAD.

    Behavioral: Healthy life style · Drug: Secondary prevention for atherosclerotic coronary artery disease · Drug: Immunosuppressive Therapy · Procedure: Coronary revascularization · Drug: Supportive therapies

Interventions

  • BehavioralHealthy life style

    Healthy diet, regular exercise, and quitting smoking

  • DrugSecondary prevention for atherosclerotic coronary artery disease

    Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

  • DrugImmunosuppressive Therapy

    Glucocorticoids and/or immunosuppressive agents

  • ProcedureCoronary revascularization

    Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

  • DrugSupportive therapies

    Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events (MACE)

    The composite endpoint including death, or Q-wave myocardial infarction, or unplanned myocardial ischemia-driven coronary revascularization (PCI or CABG), or unplanned myocardial ischemia-driven hospitalization.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

Secondary outcomes

  1. Death

    All-cause death.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

  2. Q-wave myocardial infarction

    Myocardial injury due to myocardial ischemia, resulting in newly formed pathological Q waves in ≥ 2 contiguous leads or equivalent manifestations on electrocardiogram.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

  3. Unplanned myocardial ischemia-driven coronary revascularization

    Unplanned coronary revascularization (PCI or CABG) due to myocardial ischemia.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

  4. Unplanned myocardial ischemia-driven hospitalization

    Unplanned hospitalization due to myocardial ischemia.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

  5. Walking distance in 6 minutes

    The result of 6-minute walk test (6MWT).

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  6. Target lesion minimal lumen area (TL-MLA)

    The minimum lumen area of the target lesion on optical coherence tomography (OCT).

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  7. Target lesion percent area stenosis (TL-%AS)

    Percent area stenosis (% AS) = { \[ ( proximal RLA + distal RLA ) - (MLA × 2) \] / ( proximal RLA + distal RLA ) } × 100% in the cross-section with the MLA of the target lesion on optical coherence tomography (OCT). RLA = reference lumen area; MLA = minimum lumen area; % AS = percent area stenosis.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  8. SYNTAX score

    The result of SYNTAX score calculation.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  9. Number of vessel segments with coronary lesions

    Number of vessel segments with diameter stenosis ≥ 50% on coronary angiogram.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  10. Erythrocyte sedimentation rate (ESR)

    The result of erythrocyte sedimentation rate (ESR) test.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  11. High-sensitivity C-reactive protein (hs-CRP)

    The result of serum high-sensitivity C-reactive protein (hs-CRP) test.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  12. Interleukin-6 (IL-6)

    The result of serum interleukin (IL)-6 test.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

  13. Tumor necrosis factor-alpha (TNF-α)

    The result of serum tumor necrosis factor-alpha (TNF-α) test.

    Time frame: At the beginning (diagnosis of INR-CAD) and the end of the 24-month clinical follow-up.

Other outcomes

  1. Major bleeding events

    Major bleeding events evaluated according to the Bleeding Academic Research Consortium (BARC) criteria.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

  2. Severe infection events

    Infection events involving vital organs, or with complications (such as structural change and/or dysfunction of vital organs, septic shock, et al), or requiring hospitalization, or requiring treatment with intravenous antibiotics, or requiring treatment with interventional procedures or surgeries.

    Time frame: From the beginning (diagnosis of INR-CAD) to the end of the 24-month clinical follow-up.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 20 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06845410
Responsible party
LiuZhenyu (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Feb 25, 2025
Start date
Apr 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Zhenyu Liu, M.D.
Contact
Pumch_lzy@163.com
+861069155068

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion